Medicine and Dentistry
Adalimumab
66%
Certolizumab Pegol
33%
Crohn's Disease
66%
Golimumab
33%
Inflammatory Bowel Disease
100%
Infliximab
66%
Patient with Inflammatory Bowel Disease
66%
Specific Tumor
33%
TNF Inhibitor
100%
Tumor Necrosis Factor
100%
Ulcerative Colitis
66%
Keyphrases
Adalimumab
66%
Anti-tumor Necrosis Factor Therapy
100%
Certolizumab Pegol
33%
Conventional Treatment
33%
Crohn's Colitis
33%
Crohn's Disease
33%
Extraintestinal Manifestations
33%
Golimumab
33%
Inflammatory Bowel Disease
100%
Infliximab
66%
Therapeutic Benefits
33%
Tumour Necrosis Factor Inhibitor (TNFi)
100%
Ulcerative Colitis
33%
Pharmacology, Toxicology and Pharmaceutical Science
Adalimumab
50%
Certolizumab Pegol
25%
Crohn's Disease
50%
Golimumab
25%
Inflammatory Bowel Disease
100%
Infliximab
50%
Tumor Necrosis Factor
100%
Tumor Necrosis Factor Inhibitor
75%
Ulcerative Colitis
50%
Immunology and Microbiology
Adalimumab
50%
Crohn's Disease
50%
Golimumab
25%
Inflammatory Bowel Disease
100%
Infliximab
50%
TNF Inhibitor
75%
Tumor Necrosis Factor
100%
Ulcerative Colitis
50%